It would be interesting to determine the capacity for myostatin inhibitor drugs to modify murine DMD using the mdx/mTR-/- model, which has shortened telomeres, as a staple in pre-clinical trials, where the scope for modification is more comparable to human DMD [39,40]. The gene discussed is MSTN; the disease is Duchenne muscular dystrophy.